Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: Experience in a cohort of advanced hepatocellular carcinoma patients

Investigational New Drugs

Volumn 30, Issue 1, 2012, Pages 376-381

  Coriat, Romain ^a,b   Mir, Olivier ^a,b   Cessot, Anatole ^a,b   Brezault, Catherine ^b   Ropert, Stanislas ^a,b   Durand, Jean Philippe ^a,b   Cacheux, Wulfran ^b   Chaussade, Stanislas ^a,b   Goldwasser, François ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Teaching Hospital Cochin ^*  (France)

Author keywords

5 fluorouracil; Chemotherapy; Cirrhotic patients; Hepatocellular carcinoma; Liver transplantation; Oxaliplatin

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM HEMORRHAGE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; LYMPHOCYTE COUNT; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PARIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856534408     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9525-0     Document Type: Article

References (14)

1. Nordenstedt H, White DL, El-Serag HB (2010) The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 42(Suppl 3):S206-S214
2. -(1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 332:1256-1261
3. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, Vilana R, Rodes J (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution. Hepatology 27:1578-83 (Pubitemid 28264682)
4. Llovet JM, Bruix J, Fuster J, Castells A, Garcia-Valdecasas JC, Grande L, Franca A, Bru C, Navasa M, Ayuso MC, Sole M, RealMI, Vilana R, Rimola A, Visa J, Rodes J (1998) Liver transplantation for small hepatocellular carcinoma: The tumornode- metastasis classification does not have prognostic power. Hepatology 27:1572-1577 (Pubitemid 28264681)
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-90
6. Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin MF, Khayat D, Opolon P, Poynard T (1998) Review article: Overview of medical treatments in unresectable hepatocellular carcinoma- an impossible meta-analysis? Aliment Pharmacol Ther 12:111-26 (Pubitemid 28059978)
7. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-109 (Pubitemid 39331023)
8. Taieb J, Bonyhay L, Golli L, Ducreux M, Boleslawski E, Tigaud JM, de Baere T, Mansourbakht T, Delgado MA, Hannoun L, Poynard T, Boige V (2003) Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 98:2664-70 (Pubitemid 37509531)
9. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351 (Pubitemid 38702845)
10. Alexandre J, Tigaud JM, Gross-Goupil M, Gornet JM, Romain D, Azoulay D, Misset JL, Goldwasser F (2002) Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol 25:198-203 (Pubitemid 34293079)
11. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, Hannoun L, Poynard T, Taieb J (2007) Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): Results of a phase II study. Cancer 109:1384-90 (Pubitemid 46466566)
12. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, Mentha G, Terris B (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460-6 (Pubitemid 38444550)
13. de Gramont A, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D (2010) Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: Simulations based on the 20,800 patient ACCENT data set. J Clin Oncol 28:460-465
14. Abou-Alfa GK, Schwartz L, Ricci S,Amadori D, SantoroA, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I,Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-300 (Pubitemid 46630787)